Literature DB >> 22351712

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

Kathleen N Ly1, Jian Xing, R Monina Klevens, Ruth B Jiles, John W Ward, Scott D Holmberg.   

Abstract

BACKGROUND: The increasing health burden and mortality from hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States are underappreciated.
OBJECTIVE: To examine mortality from HBV; HCV; and, for comparison, HIV.
DESIGN: Analysis of U.S. multiple-cause mortality data from 1999 to 2007 from the National Center for Health Statistics.
SETTING: All U.S. states and the District of Columbia. PARTICIPANTS: Approximately 22 million decedents. MEASUREMENTS: Age-adjusted mortality rates from HBV, HCV, and HIV. Logistic regression analyses of 2007 data generated 4 independent models per outcome (HCV- or HBV-related deaths) that each included 1 of 4 comorbid conditions and all sociodemographic characteristics.
RESULTS: Between 1999 and 2007, recorded deaths from HCV [corrected] increased significantly to 15,106, whereas deaths from HIV declined to 12,734 by 2007. Factors associated with HCV-related deaths included chronic liver disease, HBV co-infection, alcohol-related conditions, minority status, and HIV co-infection. Factors that increased odds of HBV-related death included chronic liver disease, HCV co-infection, Asian or Pacific Islander descent, HIV co-infection, and alcohol-related conditions. Most deaths from HBV and HCV occurred in middle-aged persons. LIMITATION: A person other than the primary physician of the decedent frequently completed the death certificate, and HCV and HBV often were not detected and thus not reported as causes of death.
CONCLUSION: By 2007, HCV had superseded HIV as a cause of death in the United States, and deaths from HCV and HBV disproportionately occurred in middle-aged persons. To achieve decreases in mortality similar to those seen with HIV requires new policy initiatives to detect patients with chronic hepatitis and link them to care and treatment. PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention.

Entities:  

Mesh:

Year:  2012        PMID: 22351712     DOI: 10.7326/0003-4819-156-4-201202210-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  325 in total

1.  Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

Authors:  Anu Osinusi; Anita Kohli; Miriam M Marti; Amy Nelson; Xiaozhen Zhang; Eric G Meissner; Rachel Silk; Kerry Townsend; Phillip S Pang; G Mani Subramanian; John G McHutchison; Anthony S Fauci; Henry Masur; Shyam Kottilil
Journal:  Ann Intern Med       Date:  2014-11-04       Impact factor: 25.391

2.  Survey of US Correctional Institutions for Routine HCV Testing.

Authors:  Curt G Beckwith; Ann E Kurth; Lauri Bazerman; Liza Solomon; Emily Patry; Josiah D Rich; Irene Kuo
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

3.  Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.

Authors:  Daniel John Smyth; Duncan Webster; Lisa Barrett; Mark MacMillan; Lisa McKnight; Frank Schweiger
Journal:  Can J Gastroenterol Hepatol       Date:  2014-11

4.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

Review 5.  Detecting viruses by using salivary diagnostics.

Authors:  Paul L A M Corstjens; William R Abrams; Daniel Malamud
Journal:  J Am Dent Assoc       Date:  2012-10       Impact factor: 3.634

Review 6.  Hepatitis C virus: an overview for dental health care providers.

Authors:  R Monina Klevens; Anne C Moorman
Journal:  J Am Dent Assoc       Date:  2013-12       Impact factor: 3.634

7.  Hepatitis C virus E2 envelope glycoprotein core structure.

Authors:  Leopold Kong; Erick Giang; Travis Nieusma; Rameshwar U Kadam; Kristin E Cogburn; Yuanzi Hua; Xiaoping Dai; Robyn L Stanfield; Dennis R Burton; Andrew B Ward; Ian A Wilson; Mansun Law
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

8.  Hepatitis C virus testing perspectives among primary care physicians in four large primary care settings.

Authors:  Amy Jewett; Arika Garg; Katherine Meyer; Laura Danielle Wagner; Katherine Krauskopf; Kimberly A Brown; Jen-Jung Pan; Omar Massoud; Bryce D Smith; David B Rein
Journal:  Health Promot Pract       Date:  2014-04-28

9.  Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use.

Authors:  Mandy D Owens; George N Ioannou; Judith L Tsui; E Jennifer Edelman; Preston A Greene; Emily C Williams
Journal:  Drug Alcohol Depend       Date:  2018-05-08       Impact factor: 4.492

10.  Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines.

Authors:  Wendy Landier; Saro H Armenian; Jin Lee; Ola Thomas; F Lennie Wong; Liton Francisco; Claudia Herrera; Clare Kasper; Karla D Wilson; Meghan Zomorodi; Smita Bhatia
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.